Qureight

#3D deep learning imaging #Deep learning #Drug discovery #Financing #Imaging #Qureight #Series B financing

Qureight closes $20 million Series B financing 

Cambridge data analytics company Qureight has raised $20 million in a Series B financing, led by Molten Ventures, which will support expansion of the Company’s 3D deep learning imaging portfolio, alongside commercial expansion to address demand across key new therapeutic markets for lung and heart diseases.  Existing investors Hargreave Hale… Read More

#News

#Mediar Therapeutics #Qureight #Sclerosis

Mediar selects Qureight to support systemic sclerosis trial 

Biotechnology company Mediar Therapeutics has enlisted the support of CRO Qureight in the Phase II trial of a treatment for systemic sclerosis.  Qureight’s AI 3D quantitative imaging analytics platform and services will be used to support Mediar’s Phase II EncompaSSc clinical trial. The trial will evaluate MTX-474, a monoclonal antibody therapeutic for people with diffuse cutaneous systemic sclerosis (dcSSc).  Systemic… Read More

#Business & Investment #News

#AI #Heart disease #Lung disease #Qureight

Qureight appoints Rebecca Simmons as COO 

Techbio company Qureight has appointed Rebecca Simmons as the company’s Chief Operating Officer.  Simmons will be responsible for scaling the company’s global business operations and leading sustainable growth initiatives. The appointment comes as Qureight aims to drive adoption and integration of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials for… Read More

#News

#AI #Heart disease #Lung disease #Qureight

Qureight appoints Dr Steven Bishop as CMO 

Techbio company Qureight has announced the appointment of Dr Steven Bishop as Chief Medical Officer.  Bishop previously served as Chief Data Officer for the company, which uses AI-powered CT imaging biomarkers and its clinical data management platform to advance understanding of lung and heart diseases.  As CMO, Bishop… Read More

#News

Fibrosis lungs
#3D imaging #Artificial intelligence (AI) #Calluna Pharma #Idiopathic pulmonary fibrosis #Imaging #Phase II trial #Qureight

AI 3D imaging platform supports Calluna’s IPF trial

Calluna Pharma will use Qureight’s AI-powered imaging and clinical data curation platform to support its Phase II AURORA study.   Qureight will analyse imaging data from adult patients, evaluating anatomical lung changes in individuals treated with CAL101, Calluna’s lead asset for the treatment of idiopathic pulmonary fibrosis (IPF). Read More

#News

#Clinical trials #Lung disease #Qureight

Synthetic study arms validate rare lung disease treatment

Qureight’s digitally-twinned synthetic control arm has been used in a breakthrough clinical trial application in place of a human placebo group, marking a world-first in lung disease research. The study, presented at the American Thoracic Society, demonstrates significant clinical efficacy for Avalyn’s inhaled pirfenidone (AP01), a promising treatment for idiopathic… Read More

#News

#Deep learning #Idiopathic pulmonary fibrosis #Imaging #Phase II trial #Qureight

Deep-learning imaging technology to enhance Phase II trial

Biopharmaceutical company Rein Therapeutics and core imaging laboratory Qureight have announced plans to collaborate on an idiopathic pulmonary fibrosis (IPF) clinical trial.  The companies will integrate Qureight’s deep-learning platform into Rein’s planned Phase II trial of its lead asset LTI-03, a novel, multi-pathway, Caveolin-1-related peptide.  … Read More

#News

Fibrosis lungs
#Artificial intelligence (AI) #Deep learning #Idiopathic pulmonary fibrosis #Partnership #Phase I trial #Qureight #Remedy Cell

Deep learning provides enhanced imaging analysis in IPF trial

Qureight and biopharmaceutical company Remedy Cell have agreed a partnership to validate RC-0315’s mechanism of action in idiopathic pulmonary fibrosis (IPF).  The primary objective of the RC-0315 Phase Ib clinical study is to measure drug safety and tolerability.   The study’s exploratory objectives will assess the… Read More

#News

Fibrosis lungs
#Avalyn Pharma #Deep learning #Fibrosis #Phase II trial #Qureight

Deep learning to provide insights in pulmonary fibrosis trial 

Qureight and Avalyn Pharma have announced the initiation of a strategic partnership in progressive pulmonary fibrosis, commencing with the ongoing MIST study.  The MIST study is a Phase IIb clinical trial evaluating the safety and efficacy of AP01 (inhaled pirfenidone) in patients with progressive pulmonary fibrosis (PPF). Read More

#News

Qureight platform image
#AI / data analytics / healthtech / informatics #AstraZeneca #Lung disease #Qureight

Qureight and AZ collaborate on lung disease research

Cambridge data analytics company Qureight has announced a multi-year strategic research collaboration with AstraZeneca. The agreement will allow AstraZeneca to use Qureight’s proprietary platform and artificial intelligence (AI) technology to conduct research across a range of complex lung diseases. It is hoped that this will help… Read More

#News